
When Norwegian biotech firm Nykode Therapeutics meets for its general assembly on Dec. 22, a new face will join as chairman of the board of directors.
The company, which was named Vaccibody until recently, announces the board's decision to propose Martin Nicklasson as the new chair, replacing Anders Tuv, who has left the role but has remained as an ordinary member of the board.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app